Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2022.12648 MMR-25-04-12648 Articles Omentin-1 induces osteoblast viability and differentiation via the TGF-β/Smad signaling pathway in osteoporosis TangCuisong 1 * LiangDengpan 2 * QiuYuyou 3 ZhuJingqi 3 TangGuangyu 1 Department of Radiology, Clinical Medical College of Shanghai Tenth People's Hospital of Nanjing Medical University, Shanghai 200072, P.R. China Department of Cardiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China Correspondence to: Dr Guangyu Tang, Department of Radiology, Clinical Medical College of Shanghai Tenth People's Hospital of Nanjing Medical University, 301 Middle Yanchang Road, Shanghai 200072, P.R. China, E-mail: tgy17tjsy@163.com

Contributed equally

 04 2022 17 02 2022 25 4 132 24112020 13072021 Copyright: © Tang et al. 2022 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Osteoporosis is a bone-related disease that results from impaired bone formation and excessive bone resorption. The potential value of adipokines has been investigated previously, due to their influence on osteogenesis. However, the osteogenic effects induced by omentin-1 remain unclear. The aim of the present study was to determine the regulatory effects of omentin-1 on osteoblast viability and differentiation, as well as to explore the underlying molecular mechanism. The present study investigated the effects of omentin-1 on the viability and differentiation of mouse pre-osteoblast cells (MC3T3-E1) using quantitative and qualitative measures. A Cell Counting Kit-8 assay was used to assess the viability of MC3T3-E1 cells following treatment with different doses of omentin-1. Omentin-1 and bone morphogenetic protein (BMP) inhibitor were added to osteogenic induction mediums in different ways to assess their effect. The alkaline phosphatase (ALP) activity and Alizarin Red S (ARS) staining of MC3T3-E1 cells treated with omentin-1 and/or BMP inhibitor were used to examine the effects of omentin-1 on differentiation and mineralization. Western blotting was used to further explore its potential mechanism, and to study the role of omentin-1 on the viability and differentiation of osteoblasts. The results showed that omentin-1 altered the viability of MC3T3-E1 cells in a dose-dependent manner. Omentin-1 treatment significantly increased the expression of members of the TGF-β/Smad signaling pathway. In the omentin-1 group, the ALP activity of the MC3T3-E1 cells was increased, and the ARS staining area was also increased. The mRNA and protein expression levels of BMP2, Runt-related transcription factor 2, collagen1, osteopontin, osteocalcin and osterix in the omentin-1 group were also significantly upregulated. All these effects were reversed following treatment with SIS3 HCl. These results demonstrated that omentin-1 can significantly promote osteoblast viability and differentiation via the TGF-β/Smad signaling pathway, thereby promoting bone formation and preventing osteoporosis.

 omentin-1 osteoblasts osteoporosis TGF-β/Smad signaling pathway Funding: No funding was received. Introduction

Osteoporosis is a debilitating disease that predominantly affects elderly individuals worldwide (1). At present, >200 million patients suffer from osteoporosis worldwide (2). According to research statistics, >1.6 million fractures are caused by osteoporosis (3,4). For women aged >50 years, the risk of suffering from fractures due to osteoporosis is 40–50% (5). Osteoporosis is a systemic skeletal disease that is characterized by a decrease in mass and deterioration of the bone microstructure (6). The consequences brought on by osteoporosis are bone fragility and susceptibility to fractures, and this can cause brittle fractures (7). At the cellular level, the pathogenesis of osteoporosis is primarily related to the disruption of bone remodeling (8). Bone remodeling primarily depends on osteoblast osteogenesis and osteoclast bone absorption, so as to maintain a certain balance (9). When a disease or aberrant inflammation disrupt this balance, osteoporosis may occur (10).

In bone tissues, osteoblasts originate from mesenchymal stem cells (MSCs), whereas osteoclasts are derived from hematopoietic stem cells (11). The differentiation of osteoblasts is achieved through the initial organic phase, which is production of collagen matrix, and the final inorganic phase, which is mineralization by hydroxyapatite crystals on the collagen scaffold (12). After the completion of matrix secretion and mineralization, the osteoblasts, which are embedded in the matrix, are known as bone cells, whereas the osteoblasts remaining on the bone surface turn into flattened lining cells or gradually undergo apoptosis. Importantly, bone marrow MSCs (BMSCs) are pluripotent. Apart from osteoblasts, BMSCs can differentiate into several different cell types, including adipocytes, myocytes, chondrocytes, endothelial cells and vascular smooth muscle cells (13). Amongst these cell lineages, adipogenic differentiation is particularly relevant to the homeostasis of bone, as cells undergoing osteoblast formation can be diverted to adipocytes, leading to the loss of these cells from the osteoblast pool and the reduction of overall osteogenic potential (13).

The imbalance of adipocyte differentiation and regulation of osteoblasts is commonly seen in aging and diabetic individuals, which can lead to the impairment of fat bone marrow, impairment of osteoblast renewal and an increase in the incidence of chronic bone loss (13–15). Beyond that, adipocytes secrete a series of biologically active signaling molecules, which can also influence bone homeostasis. It has been reported that several of these molecules, including chemorin, resistin, visfatin, leptin and adiponectin, affect the development and function of osteoblasts and osteoclasts (16–21).

Omentin-1, a 34 kDa adipokine selectively expressed in omental adipose tissue, is abundant in the plasma (22,23). Omentin-1 has been demonstrated to serve as a significant factor in multiple physiological processes, including insulin action, cardiovascular function and the inflammatory response (23–25). A previous study demonstrated that omentin-1 plays an important role in protecting against vascular calcification (26). A clinical study has also shown that omentin-1 levels are inversely correlated with obesity and insulin resistance (27). Regarding its effects on bone, a previous study reported that circulating omentin-1 levels were inversely correlated with bone mineral density (BMD) in the lumbar region of the spine in Iranian postmenopausal women (28). The levels of circulating omentin-1 correlates positively with adiponectin and negatively with body mass index and the leptin levels (29). In a co-culture system of osteoblasts and osteoclast precursors, omentin-1 can reduce osteoclast formation by stimulating osteoprotegerin (OPG) (30). To date, only a few studies have investigated the association between omentin-1 and osteoblast proliferation and differentiation. Moreover, the osteogenic effect induced by omentin-1 remains unclear. The TGF-β/Smad signaling pathway is involved in the regulation of cell differentiation and it is a key pathway related to osteogenesis (31–33). To understand the underlying mechanism driving the effects of omentin-1 on osteogenic differentiation in MC3T3-E1, the role of the TGF-β/Smad pathway in this process was investigated. The aim of the present study was to determine the regulatory effects of omentin-1 on osteoblast viability and differentiation, as well as to explore the underlying molecular mechanism.

 Materials and methods <sec> <title>Cell culture and treatment

Mouse embryo osteoblast precursor cell line MC3T3-E1 was obtained from American Type Culture Collection (ATCC, CRL-2593™). The cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (HyClone; Cytiva) and 1% penicillin/streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO2 humidified incubator. In order to stimulate osteogenic induction, the MC3T3-E1 cells were seeded in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10 mM β-glycerophosphate, 50 µg/ml ascorbic acid and 10 nM dexamethasone (all Sigma-Aldrich; Merck KGaA) (34). Subsequently, cells were treated with different doses of omentin-1 (100, 500 and 1,000 ng/ml; Cell Science, Inc.) for 24 h at 37°C and/or 3 µM SIS3 HCl (Selleck Chemicals) for 6 h at 37°C for the following experiments.

 Reverse transcription-quantitative (RT-q)PCR

Total RNA was extracted from cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). iScript™ Reverse Transcription SuperMix kit (Bio-Rad Laboratories, Inc.) was used to reverse transcribe 2 µg RNA into cDNA according to the manufacturer's protocol. qPCR was performed using SYBR-Green MasterMix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on an ABI PRISM 7900 Sequence Detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR amplification program was as follows: 94°C for 60 sec, followed by 40 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 60 sec. The primer sequences used for PCR were as follows: Bone morphogenetic protein 2 (BMP2) forward, 5′-AGCCCTTCACTGCCATCCTGT-3′ and reverse, 5′-ATTCTCTCGTTCACCGCCCAC-3′; Runt-related transcription factor 2 (Runx2) forward, 5′-CCCAACTTCCTGTGCTCC-3′ and reverse, 5′-AGTGAAACTCTTGCCTCGTC-3′; Collagen1 forward, 5′-TAAGGGTGACAGAGGCGATG-3′ and reverse, 5′-GGACCGCTAGGACCAGTTTC-3′; osteopontin (Opn) forward, 5′-TCCAAAGTCAGCCAGGAATCC-3′ and reverse, 5′-CGGAGTTGTCTGTGCTCTTCA-3′; osteocalcin (Ocn) forward, 5′-CTCCTTACCCGGATCCCCTG-3′ and reverse, 5′-GTAGAAGCGCTGGTAGGCGT-3′; Osterix forward, 5′-TCCCTGGATATGACTCATCCCT-3′ and reverse, 5′-CCAAGGAGTAGGTGTGTTGCC-3′; and GAPDH forward, 5′-GGGAAACTGTGGCGTGAT-3′ and reverse, 5′-GAGTGGGTGTCGCTGTTGA-3′. Gene expression analysis was performed using the 2−ΔΔCq method (35) and normalized to GAPDH.

 Cell viability

The cells were cultured in 96-well culture plates at a density of 2×104 cells/well. After 3 days, a Cell Counting Kit-8 (CCK-8) assay (Beyotime Institute of Biotechnology) was performed to evaluate cell viability. The CCK-8 solution was added to each group, and the cells were incubated at 37°C for 1 h. The absorbance of each well was measured at a wavelength of 450 nm using a microplate spectrophotometer.

 Western blot assay

Cells in the different treatment groups were lysed using RIPA lysis buffer (Beyotime Institute of Biotechnology) and protein concentrations were measured using Bradford reagent (Bio-Rad Laboratories, Inc.). Equal quantities of proteins (40 µg/lane) were separated via 10% SDS-PAGE (Bio-Rad Laboratories, Inc.) and transferred to a PVDF membrane (MilliporeSigma). After being blocked with 5% non-fat milk in 0.1% tris-buffered saline with Tween-20 for 1 h at room temperature, the membranes were incubated with primary antibodies against BMP2 (1:1,000; cat. no. ab214821; Abcam), phosphorylated (p)-Smad1 (1:1,000; cat. no. ab226821; Abcam), p-Smad5 (1:2,000; cat. no. ab92698; Abcam), Smad1 (1:1,000; cat. no. ab33902; Abcam), Smad5 (1:1,000; cat. no. ab40771; Abcam), Runx2 (1:1,000; cat. no. ab236639; Abcam), collagen1 (1:1,000; cat. no. ab138492; Abcam), Opn (1:1,000; cat. no. ab63856; Abcam), Ocn (1:1,000; cat. no. ab133612; Abcam) and osterix (1:1,000; cat. no. ab209484; Abcam) and GAPDH (1:2,500; cat. no. ab9485; Abcam) overnight at 4°C, and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (1:1,000; cat. no. #7074; Cell Signaling Technology, Inc.) for 1 h at room temperature. The blots were then visualized using an enhanced chemiluminescence system (Beyotime Institute of Biotechnology). Densitometry analysis was performed using ImageJ (Version 1.49; National Institutes of Health).

 Cell differentiation analysis

Alkaline phosphatase (ALP) activity, an early biochemical marker widely used to assess osteogenic activity, was measured. Briefly, the cells were seeded in 12-well culture plates at a density of 4×104 cells per ml for 7 days. Subsequently, the cells were fixed in 4% paraformaldehyde for 30 min at room temperature, followed by treatment with nitroblue tetrazolium (Sigma-Aldrich; Merck KGaA) and 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich; Merck KGaA) for 2 h at room temperature. Cells were washed with deionized water and observed under an inverted light microscope (Nikon Corporation; ×200 magnification).

 Cell mineralization analysis

Mineralization was evaluated by quantifying the formation of calcium phosphate in cells using an Alizarin Red Staining (ARS) kit (Sigma-Aldrich; Merck KGaA). Briefly, the cells were cultured in 12-well culture plates at a density of 4×104 cells per ml. After 21 days, the cultured cells were fixed with 95% ethanol for 10 min at room temperature. To stain the calcium deposits, 2% ARS solution (Sigma-Aldrich; Merck KGaA) was applied for 15 min at room temperature. To measure the degree of mineralization, the ARS released from the cell matrix was incubated in cetyl pyridinium chloride for 15 min at room temperature and quantified by spectrophotometry at 540 nm.

 Statistical analysis

Data are presented as the mean ± standard deviation of three independent experiments. Differences between groups were determined using an unpaired two-tailed Student's t-test for comparisons between two groups, and one-way ANOVA with a post hoc Tukey's test was used for comparisons between multiple groups. Statistical analysis was performed using SPSS 13.0 (SPSS, Inc.). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Omentin-1 stimulates viability of osteoblasts

The effect of omentin-1 on MC3T3-E1 cell viability was assessed using a CCK-8 assay. As shown in Fig. 1, the viability of osteoblasts was altered in a dose-dependent manner following treatment with omentin-1, and the effect was significant when treated with 1,000 ng/ml omentin-1 after 3 days of treatment.

 Omentin-1 activates the Smad signaling pathway and increases BMP2 expression in osteoblasts

To explore the potential mechanisms by which omentin-1 exerted its effects on osteoblasts, western blotting was performed. As shown in Fig. 2, omentin-1 at a dose of 1,000 ng/ml increased the protein expression levels of BMP2, p-Smad1 and p-Smad5 (P<0.05). However, 1,000 ng/ml omentin-1 did not exert a notable effect on the expression levels of Smad1 and Smad5.

 Omentin-1 promotes the viability of osteoblasts through the TGF-β/Smad signaling pathway

As shown in Fig. 3A and B, SIS3 HCl, a Smad inhibitor, significantly inhibited BMP2 protein levels and phosphorylation of Smad1 and Smad5 compared with the control group, while 1,000 ng/ml omentin-1 significantly increased the expression levels of the three proteins. Meanwhile, SIS3 HCl attenuated the effects of omentin-1 on the expression of BMP2, p-Smad1 and p-Smad5 in MC3T3-E1 cells. In addition, CCK-8 analysis showed a significant increase in cell viability in omentin-1-treated MC3T3-E1 cells, and this increase in viability was significantly attenuated by SIS3 HCl (Fig. 3C).

 Omentin-1 regulates differentiation and mineralization of osteoblasts via the TGFβ/Smad signaling pathway

Next, the effects of omentin-1 on osteoblasts were assessed. As shown in Fig. 4A and B, ARS staining in the omentin-1-treated cells showed an increased mineralization rate compared with the control group, and SIS3 HCl significantly attenuated the omentin-1-induced mineralization. In addition, ALP activity was significantly increased in the omentin-1 group, whereas SIS3 HCl significantly weakened the activity of ALP in MC3T3-E1 cells (Fig. 4C).

 Analysis of cellular Runx2, collagen1, Opn, Ocn and osterix expression

Data from RT-qPCR and western blot assays showed that the expression levels of osteogenesis-related proteins, including BMP2, Runx2, collagen1, Opn, Ocn and osterix, were significantly upregulated in the omentin-1 group. However, the expression levels of these proteins in MC3T3-E1 cells treated with SIS3 HCl were significantly reduced (Fig. 5A-C).

 Discussion

Bone remodeling and skeletal homeostasis are dynamic life-long processes that rely on the balance and integrated actions between osteoblastic bone formation and osteoclastic bone resorption (36–38). Osteoblastic lineage cells interact with osteoclastic lineage cells, which is necessary for the formation of functional osteoclasts (39). Certain bone-related diseases, such as osteoporosis, rheumatoid arthritis and osteoarthritis, are associated with abnormal bone metabolism and accelerated bone loss (40). Bone formation and repair are intrinsically associated with the balanced activity of osteoblasts (41). Osteoblasts are responsible for bone matrix secretion and mineralization, and they tightly regulate osteoclast activation and differentiation (42). Dysfunctional behaviors of osteoblasts lead to improper bone matrix deposition and mineralization, affecting the size, shape and integrity of the skeletal structures (43).

MC3T3-E1, a popular osteoblast cell line that represents a pre-osteoblastic phenotype, is a mouse calvaria clonal cell line that has given rise to several subclones (44). Decreased proliferative activities have been observed at passage numbers above 36, whereas their replicative senescence has been displayed when these cells reach a high passage number of 60, which is similar to that of human cells, at which point they show inconsistent cell cycling (45). This important feature also makes these cells suitable as novel models for in vitro bone research, including bone remodeling and formation (46).

Omentin-1, which was discovered from a human omental fat cDNA library, is primarily expressed in visceral adipose tissue (23). Omentin-1 can promote osteogenic differentiation, although this has been contested (47–52). Therefore, the present study investigated the effects of omentin-1 on MC3T3-EI cells by observing proliferation patterns, with the aim of determining the regulatory effect of omentin-1 and identifying the underlying molecular mechanisms. When MC3T3-E1 cells were treated with different concentrations of omentin-1 (100-1,000 ng/ml) for 3 days, the viability of MC3T3-E1 cells increased significantly. Additionally, the effect of omentin-1 was weakened after adding a BMP inhibitor. This suggested that omentin-1 could stimulate the viability of osteoblasts. Based on these experiments, 1,000 ng/ml omentin-1 was used for subsequent experiments, and 0 ng/ml omentin-1 was used as the control group to further study the effects of omentin-1 on osteoblasts.

Regulation of gene expression by TGF-β is achieved primarily through the initiation of intracellular signal transduction and the activation of the Smad signaling pathway (53,54). TGF-β promotes osteogenic differentiation, and at the same time, it also inhibits adipogenic differentiation of human MSCs (55). The TGF-β/Smad pathway is also key to adipogenesis (56). TGF-β inhibits adipogenic differentiation in human preadipocytes, which is mediated primarily by the Smad family members (57,58). Smad3 inhibits adipogenic conversion, whereas interfering with Smad3 function confers resistance to inhibition of adipogenesis by TGF-β (56). The present results showed that SIS3 HCL treatment significantly inhibited the protein expression levels of BMP2, p-SMAD1 and p-SMAD5, while 1,000 ng/ml omentin-1 increased the protein expression levels of BMP2 and p-Smad1/5. However, 1,000 ng/ml omentin-1 exerted no effect on Smad1 and Smad5, which are also members of the TGF-β/Smad pathway.

To confirm the effects of the omentin-1/TGF-β/Smad pathway on MC3T3-E1 cells, cells were pretreated with a selective BMP TGF-β/Smad signaling inhibitor, SIS3 HCl (3 µM per day), 3 days prior to treatment with 1,000 ng/ml omentin-1. Cell viability was promoted in the 1,000 ng/ml omentin-1 group, and SIS3 HCl attenuated the increase in viability mediated by omentin-1. The results from the CCK-8 assays revealed that omentin-1 significantly promoted the viability ability of the MC3T3-E1 cells via the TGF-β/Smad pathway.

In previous years, several studies have investigated the relationship between omentin-1 and bone metabolism. On the one hand, adiponectin has been shown to induce osteoblast proliferation and differentiation (50), as well as to increase bone mass via osteoclastogenesis suppression and osteoblastogenesis activation (51), and the results of the present study were in agreement with these previous findings. Conversely, adiponectin has been verified to induce osteoclast formation via stimulation of RANKL and inhibition of OPG production (48,49). This suggests that adipokines also serve an important role in osteoclastic balance; thus the effects of adipokines on osteoclasts should form the basis of future studies. A previous study showed that there was an inverse correlation between omentin-1 and broadband ultrasound attenuation levels in postmenopausal women. This association was not mediated by OPG levels (52). The results from in vitro and in vivo studies have shown contradictory results. Results from a meta-analysis of observational studies demonstrated an inverse relationship between adiponectin levels and BMD, with five studies showing a negative association, and another five showing no association (47). The reasons for such discrepant findings are unclear, but it is conceivable that the microenvironment in human bodies can be affected by various factors. The ability of cell culture and animal models to emulate the complex processes that take place in the human body is limited, such as possible adiponectin-dependent counter-regulatory mechanisms.

Osteoporosis, a type of bone-related disease, results from impaired bone formation and excessive bone resorption. Current strategies to augment bone formation, such as the use of growth factors (59), have shown promising results. However, the osteoblast lineage specification and bone regeneration remain unclear. An improved understanding of these may considerably improve the therapeutic strategies available. In order to determine how omentin-1 guides osteoblast bone formation, the effects of several potential mediators involved in the pro-osteogenic pathway were assessed using western blotting in the current study. Osteoblasts are derived from osteoprogenitors that differentiate by progressively expressing maturation markers (60). Runx2 is a transcription factor that serves a role in osteoblast differentiation. Previous studies have shown that silencing of Runx2 can block the differentiation of osteoblasts in mice (61,62). Patients with cleidocranial dysplasia, which is caused by heterozygous mutations in the Runx2 gene, are characterized by an underdeveloped collarbone, short stature, excess teeth, fontanelle patency and other bone growth-related defects (63). Osterix is a zinc finger transcription factor present in osteoblasts and serves a leading role in the osteoblast differentiation process (63). A previous study showed that Runx2 can regulate the levels of osterix (64). Collagen-1 is a primary structural protein present in the extracellular space in the bone, making up 25–35% of the entire-body protein content (65). Depending upon the degree of mineralization, collagen tissues may be rigid (bone), compliant (tendon) or have a gradient from rigid to compliant (cartilage) (66). As the skeleton is the main structural component of the body, collagen-1 is responsible for maintaining the strength of these structures (67). Opn is also known as bone sialoprotein I, a protein in humans encoded by the SPP1 gene (68). Ocn is a vitamin K-dependent calcium-binding protein (69). Opn and Ocn are two typical biomarkers of osteoblasts, and are involved in osteogenic differentiation and the mineralization of extracellular matrix during bone formation and repair (70,71). Previous studies have shown that Runx2 stimulates the differentiation of MSCs into osteoblasts by regulating Opn and Ocn activity (61,72). In the present study, it was shown that omentin-1 significantly upregulated the expression of Runx2, Collagen-1, Opn, Ocn and osterix, suggesting that it accelerated bone formation.

Based on the aforementioned results, it was noticed in the present study that SIS3 HCL treatment alone only affected the TGF-β/Smad pathway, but had no significant effects on the viability, differentiation and mineralization of osteoblasts and the expression of osteogenesis-related proteins. However, SIS3 HCL exerted obvious roles when the cells were treated with omentin-1. Hence, we speculated that under normal conditions, osteoblasts were only partially affected by SIS3 HCL except for the expression of TGF-β/Smad pathway, but omentin-1 had significant promoting effects on cell differentiation and mineralization via regulating the TGF-β/Smad pathway. Thus, there is a noticeable effect of SIS3 HCL on biological function and signaling and omentin-1-mediated osteoblasts.

In conclusion, the present study examined the potential effects of omentin-1 on the viability and differentiation of osteoblasts and the signaling pathways involved (Fig. 6). Omentin-1 promoted osteoblast viability in a dose-dependent manner. Western blotting revealed that omentin-1 induced the activation of BMP2 and p-Smad1/5. Furthermore, omentin-1 promoted osteoblast viability, differentiation and mineralization, and these effects were impeded by a TGF-β/Smad inhibitor. These findings indicated that omentin-1 promoted osteoblast viability and differentiation via the TGF-β/Smad signaling pathway, suggesting that omentin-1 may be a potential target in the treatment of osteoporosis.

 Acknowledgements

Not applicable.

 Availability of data and materials

All data generated or analyzed during this study are included in this published article.

 Authors' contributions

CT, DL and GT designed the study, drafted and revised the manuscript. YQ and JZ analyzed the data and searched the literature. CT, DL, YQ and JZ performed the experiments. CT and GT confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References MillerPDManagement of severe osteoporosisExpert Opin Pharmacother17473488201610.1517/14656566.2016.112485626605922 NohJYYangYJungHMolecular mechanisms and emerging therapeutics for osteoporosisInt J Mol Sci217623202010.3390/ijms2120762333076329 ClarkSOsteoporosis-the disease of the 21st century?Lancet3591714200210.1016/S0140-6736(02)08662-212049857 CooperCEpidemiology of osteoporosisOsteoporos Int9(Suppl 2)S2S8199910.1007/PL0000415610525719 JohnellOKanisJEpidemiology of osteoporotic fracturesOsteoporos Int16(Suppl 2)S3S7200510.1007/s00198-004-1702-615365697 StrakaMStraka-TrapezanlidisMDeglovicJVargaIPeriodontitis and osteoporosisNeuro Endocrinol Lett36401406201526707036 KurraSFinkDASirisESOsteoporosis-associated fracture and diabetesEndocrinol Metab Clin North Am43233243201410.1016/j.ecl.2013.09.00424582100 LaneNEEpidemiology, etiology, and diagnosis of osteoporosisAm J Obstet Gynecol194(Suppl 2)S3S11200610.1016/j.ajog.2005.08.04716448873 BaccaroLFCondeDMCosta-PaivaLPinto-NetoAMThe epidemiology and management of postmenopausal osteoporosis: A viewpoint from BrazilClin Interv Aging10583591201510.2147/CIA.S5461425848234 LaneJMRussellLKhanSNOsteoporosisClin Orthop Relat Res372139150200010.1097/00003086-200003000-0001610738423 ChenXWangZDuanNZhuGSchwarzEMXieCOsteoblast-osteoclast interactionsConnect Tissue Res5999107201810.1080/03008207.2017.129008528324674 JayakumarPDi SilvioLOsteoblasts in bone tissue engineeringProc Inst Mech Eng H22414151440201010.1243/09544119JEIM82121287829 MalhotraAHabibovicPCalcium phosphates and angiogenesis: Implications and advances for bone regenerationTrends Biotechnol34983992201610.1016/j.tibtech.2016.07.00527481474 LeijtenJChaiYCPapantoniouIGerisLSchrootenJLuytenFPCell based advanced therapeutic medicinal products for bone repair: Keep it simple?Adv Drug Deliv Rev843044201510.1016/j.addr.2014.10.02525451134 WeiDXDaoJWChenGQA Micro-Ark for Cells: Highly open porous polyhydroxyalkanoate microspheres as injectable scaffolds for tissue regenerationAdv Mater30e1802273201810.1002/adma.20180227329920804 ShenXZhangYGuYXuYLiuYLiBChenLSequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nanohydroxyapatite scaffold for the enhancement of bone regenerationBiomaterials106205216201610.1016/j.biomaterials.2016.08.02327566869 CahillKSChiJHDayAClausEBPrevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion proceduresJAMA3025866200910.1001/jama.2009.164019567440 SkovrljBKoehlerSMAndersonPAQureshiSAHechtACIatridisJCChoSKAssociation between BMP-2 and carcinogenicitySpine (Phila Pa 1976)4018621871201510.1097/BRS.000000000000112626274524 XuCSuPChenXMengYYuWXiangAPWangYBiocompatibility and osteogenesis of biomimetic Bioglass-Collagen-Phosphatidylserine composite scaffolds for bone tissue engineeringBiomaterials3210511058201110.1016/j.biomaterials.2010.09.06820980051 ZhangYFanWMaZWuCFangWLiuGXiaoYThe effects of pore architecture in silk fibroin scaffolds on the growth and differentiation of mesenchymal stem cells expressing BMP7Acta Biomater630213028201010.1016/j.actbio.2010.02.03020188872 HolzwarthJMMaPXBiomimetic nanofibrous scaffolds for bone tissue engineeringBiomaterials3296229629201110.1016/j.biomaterials.2011.09.00921944829 SchafflerANeumeierMHerfarthHFurstAScholmerichJBuchlerCGenomic structure of human omentin, a new adipocytokine expressed in omental adipose tissueBiochim Biophys Acta173296102200510.1016/j.bbaexp.2005.11.00516386808 YangRZLeeMJHuHPrayJWuHBHansenBCShuldinerARFriedSKMcLenithanJCGongDWIdentification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin actionAm J Physiol Endocrinol Metab290E1253E1261200610.1152/ajpendo.00572.200416531507 YamawakiHKuramotoJKameshimaSUsuiTOkadaMHaraYOmentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cellsBiochem Biophys Res Commun408339343201110.1016/j.bbrc.2011.04.03921514279 YamawakiHTsubakiNMukohdaMOkadaMHaraYOmentin, a novel adipokine, induces vasodilation in rat isolated blood vesselsBiochem Biophys Res Commun393668672201010.1016/j.bbrc.2010.02.05320170632 DuanXYXiePLMaYLTangSYOmentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathwayAmino Acids4112231231201110.1007/s00726-010-0800-321082206 de Souza BatistaCMYangRZLeeMJGlynnNMYuDZPrayJNdubuizuKPatilSSchwartzAKligmanMOmentin plasma levels and gene expression are decreased in obesityDiabetes5616551661200710.2337/db06-150617329619 TohidiMAkbarzadehSLarijaniBKalantarhormoziMOstovarAAssadiMVahdatKFarrokhniaMSanjdidehZAmirinejadRNabipourIOmentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal womenBone51876881201210.1016/j.bone.2012.08.11722971441 Moreno-NavarreteJMCatalánVOrtegaFGómez-AmbrosiJRicartWFrühbeckGFernández-RealJMCirculating omentin concentration increases after weight lossNutr Metab (Lond)727201010.1186/1743-7075-7-2720380714 XieHXiePLWuXPChenSMZhouHDYuanLQShengZFTangSYLuoXHLiaoEYOmentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expressionCardiovasc Res92296306201110.1093/cvr/cvr20021750093 WangJWangMChenFWeiYChenXZhouYYangXZhuXTuCZhangXNano-hydroxyapatite coating promotes porous calcium phosphate ceramic-induced osteogenesis via BMP/Smad signaling pathwayInt J Nanomedicine1479878000201910.2147/IJN.S21618231632013 LiuZYuZChangHWangYXiangHZhangXYuBStrontium-containing α-calcium sulfate hemihydrate promotes bone repair via the TGF-β/Smad signaling pathwayMol Med Rep2035553564201931432182 WangQLLiHFWangDPLiuZYXiaoWWXuLLYuSEffect of GGCX on the differentiation function of osteoporosis bone marrow mesenchymal stem cells through regulating TGFβ/smad signaling pathwayEur Rev Med Pharmacol Sci2372247231201931539109 KimSWHerSJParkSJKimDParkKSLeeHKHanBHKimMSShinCSKimSYGhrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cellsBone37359369200510.1016/j.bone.2005.04.02015978880 SchmittgenTDLivakKJAnalyzing real-time PCR data by the comparative C(T) methodNat Protoc311011108200810.1038/nprot.2008.7318546601 LernerUHKindstedtELundbergPThe critical interplay between bone resorbing and bone forming cellsJ Clin Periodontol46(Suppl 21)3351201910.1111/jcpe.1305130623989 FiliSKaralakiMSchallerBMechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factorsCancer Lett2831019200910.1016/j.canlet.2009.01.01119201081 KearnsAEKhoslaSKostenuikPJReceptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and diseaseEndocr Rev29155192200810.1210/er.2007-001418057140 HorowitzMCXiYWilsonKKacenaMAControl of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligandsCytokine Growth Factor Rev12918200110.1016/S1359-6101(00)00030-711312114 WadaTNakashimaTHiroshiNPenningerJMRANKL-RANK signaling in osteoclastogenesis and bone diseaseTrends Mol Med121725200610.1016/j.molmed.2005.11.00716356770 LongFBuilding strong bones: Molecular regulation of the osteoblast lineageNat Rev Mol Cell Biol132738201110.1038/nrm325422189423 NakamichiYUdagawaNKobayashiYNakamuraMYamamotoYYamashitaTMizoguchiTSatoMMogiMPenningerJMTakahashiNOsteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblastsJ Immunol178192200200710.4049/jimmunol.178.1.19217182555 ValentiMTDalle CarbonareLMottesMOsteogenic differentiation in healthy and pathological conditionsInt J Mol Sci1841201610.3390/ijms1801004128035992 Wan HasanWNAbd GhafarNChinKYIma-NirwanaSAnnatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells: A temporal sequential studyDrug Des Devel Ther1217151726201810.2147/DDDT.S16893529942115 CzekanskaEMStoddartMJRichardsRGHayesJSIn search of an osteoblast cell model for in vitro researchEur Cell Mater24117201210.22203/eCM.v024a0122777949 AubinJERegulation of osteoblast formation and functionRev Endocr Metab Disord28194200110.1023/A:101001120906411704982 BiverESalliotCCombescureCGossecLHardouinPLegroux-GerotICortetBInfluence of Adipokines and Ghrelin on Bone Mineral Density and Fracture Risk: A systematic review and meta-analysisJ Clin Endocrinol Metab9627032713201110.1210/jc.2011-004721778223 LuoXHGuoLJXieHYuanLQWuXPZhouHDLiaoEYAdiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathwayJ Bone Miner Res2116481656200610.1359/jbmr.06070716995820 WangQPLiXPWangMZhaoLLLiHXieHLuZYAdiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: An in vivo studyEndocrine47845853201410.1007/s12020-014-0216-z24627163 LuoXHGuoLJYuanLQXieHZhouHDWuXPLiaoEYAdiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathwayExp Cell Res30999109200510.1016/j.yexcr.2005.05.02115963981 OshimaKNampeiAMatsudaMIwakiMFukuharaAHashimotoJYoshikawaHShimomuraIAdiponectin increases bone mass by suppressing osteoclast and activating osteoblastBiochem Biophys Res Commun331520526200510.1016/j.bbrc.2005.03.21015850790 WuSSLiangQHLiuYCuiRRYuanLQLiaoEYOmentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathwayInt J Endocrinol2013368970201310.1155/2013/36897023606838 MiyazonoKTGF-beta signaling by Smad proteinsCytokine Growth Factor Rev111522200010.1016/S1359-6101(99)00025-810708949 ten DijkePMiyazonoKHeldinCHSignaling inputs converge on nuclear effectors in TGF-beta signalingTrends Biochem Sci256470200010.1016/S0968-0004(99)01519-410664585 van ZoelenEJDuarteIHendriksJMvan der WoningSPTGFβ-induced switch from adipogenic to osteogenic differentiation of human mesenchymal stem cells: Identification of drug targets for prevention of fat cell differentiationStem Cell Res Ther7123201610.1186/s13287-016-0375-327562730 SantibanezJFKocicJTransforming growth factor-β superfamily, implications in development and differentiation of stem cellsBiomol Concepts3429445201210.1515/bmc-2012-001525436548 PetruschkeTRöhrigKHaunerHTransforming growth factor beta (TGF-beta) inhibits the differentiation of human adipocyte precursor cells in primary cultureInt J Obes Relat Metab Disord1853253619947951472 ChoyLSkillingtonJDerynckRRoles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiationJ Cell Biol149667682200010.1083/jcb.149.3.66710791980 El BialyIJiskootWReza NejadnikMFormulation, delivery and stability of bone morphogenetic proteins for effective bone regenerationPharm Res3411521170201710.1007/s11095-017-2147-x28342056 RutkovskiyAStensløkkenKOVaageIJOsteoblast differentiation at a glanceMed Sci Monit Basic Res2295106201610.12659/MSMBR.90114227667570 YangDOkamuraHQiuLUpregulated osterix expression elicited by Runx2 and Dlx5 is required for the accelerated osteoblast differentiation in PP2A Cα-knockdown cellsCell Biol Int42403410201810.1002/cbin.1090229068100 KomoriTRunx2, an inducer of osteoblast and chondrocyte differentiationHistochem Cell Biol149313323201810.1007/s00418-018-1640-629356961 MundlosSOttoFMundlosCMullikenJBAylsworthASAlbrightSLindhoutDColeWGHennWKnollJHMutations involving the transcription factor CBFA1 cause cleidocranial dysplasiaCell89773779199710.1016/S0092-8674(00)80260-39182765 NakashimaKZhouXKunkelGZhangZDengJMBehringerRRde CrombruggheBThe novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formationCell1081729200210.1016/S0092-8674(01)00622-511792318 VarmaSOrgelJPSchieberJDNanomechanics of type I collagenBiophys J1115056201610.1016/j.bpj.2016.05.03827410733 MurshedMMechanism of bone mineralizationCold Spring Harb Perspect Med8a031229201810.1101/cshperspect.a03122929610149 KislingALustRMKatwaLCWhat is the role of peptide fragments of collagen I and IV in health and disease?Life Sci2283034201910.1016/j.lfs.2019.04.04231004660 ChenYOuYDongJYangGZengZLiuYLiuBLiWHeXLanTOsteopontin promotes collagen I synthesis in hepatic stellate cells by miRNA-129-5p inhibitionExp Cell Res362343348201810.1016/j.yexcr.2017.11.03529196165 AnJYangHZhangQLiuCZhaoJZhangLChenBNatural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formationLife Sci1474658201610.1016/j.lfs.2016.01.02426796578 ZhouHChoongPMcCarthyRChouSTMartinTJNgKWIn situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivoJ Bone Miner Res914891499199410.1002/jbmr.56500909227817834 van LeeuwenJPvan DrielMvan den BemdGJPolsHAVitamin D control of osteoblast function and bone extracellular matrix mineralizationCrit Rev Eukaryot Gene Expr11199226200111693961 TakahashiTKatoSSuzukiNKawabataNTakagiMAutoregulatory mechanism of Runx2 through the expression of transcription factors and bone matrix proteins in multipotential mesenchymal cell line, ROB-C26J Oral Sci47199207200510.2334/josnusd.47.19916415564

Effects of different concentrations of omentin-1 on the viability of MC3T3-E1 cells. Cell Counting Kit-8 assay was performed to assess cell viability. Results are expressed as the mean ± SD. ***P<0.001 vs. control.

Effects of omentin-1 on the expression of genes related to the TGF-β/Smad pathway. Western blotting was used to detect the protein levels of the TGF-β/Smad pathway. Results are expressed as the mean ± SD. **P<0.01, ***P<0.001 vs. control. TGF-β, transforming growth factor-β; BMP2, bone morphogenetic protein 2; p-, phosphorylated.

Effects of omentin-1/TGF-β/Smad signaling on the viability of osteoblasts and quantitative analyses. (A and B) Western blot assay was utilized to measure the protein levels of TGF-β/Smad pathway. (C) Cell viability was evaluated via a Cell Counting Kit-8 assay. Results are expressed as the mean ± SD. *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, ##P<0.01, ###P<0.001 vs. SIS3 HCl group; ΔP<0.05, ΔΔΔP<0.001 vs. 1,000 ng/ml omentin-1 group. TGF-β, transforming growth factor-β; BMP2, bone morphogenetic protein 2; p-, phosphorylated.

Effects of omentin-1/transforming growth factor-β/Smad signaling on the differentiation and mineralization of osteoblasts. (A and B) Mineralization was identified by an Alizarin Red Staining kit. Original magnification, ×200. (C) ALP activity was measured using an ALP kit. ***P<0.001 vs. control; #P<0.05 vs. SIS3 HCl group; ΔΔΔP<0.001 vs. 1,000 ng/ml omentin-1 group. ALP, alkaline phosphatase.

Effects of omentin-1/transforming growth factor-β/Smad signaling on the expression of genes related to bone formation. (A and B) Western blotting analysis was applied for protein detection of BMP2, Runx2, Collagen1, Opn, Ocn and Osterix. (C) mRNA levels of BMP2, Runx2, Collagen1, Opn, Ocn and Osterix were measured by reverse transcription-quantitative PCR. ***P<0.001 vs. control; #P<0.05, ##P<0.01, ###P<0.001 vs. SIS3 HCl group; ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 vs. 1,000 ng/ml omentin-1 group. BMP2, bone morphogenetic protein 2; Runx2, runt-related transcription factor 2; Opn, osteopontin; Ocn, osteocalcin.

Proposed schematic diagram for the regulatory effects of omentin-1 on the viability and differentiation of osteoblasts via the transforming growth factor-β/Smad signaling pathway in osteoporosis. BMP2, bone morphogenetic protein 2.